Loading patent…
OwnerKenneth Stephen Albert, Theophilus Jones Gana +1inventors
InventorsKenneth Stephen Albert, Theophilus Jones Gana, Paul Maes
Estimating the term…
A method of treating or preventing myocardial ischemia in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem associated with excipients to provide controlled (sustained) release of the form of Diltiazem for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours after administration, the preparation comprising the form of Diltiazem in oral sustained-release dosage form in which the Diltiazem is adapted to be released after administration over a prolonged period of time and exhibits when given to humans (i) a higher bioavailability when given at night compared to when given in the morning without food according to FDA guidelines or criteria and (ii) bioequivalence when given in the morning with and without food according to the same FDA guidelines or criteria.
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the form of Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the form of Diltiazem
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration, the preparation being in a sustained-release dosage form in which the form of Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the form of Diltiazem
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the form of Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time and being adapted to release the Diltiazem
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent in which the core and membrane comprise:
A method of treating or preventing myocardial ischemia and angina in a patient in need thereof comprising administration of a controlled-release Galenical preparation of pharmaceutically acceptable form of Diltiazem including the pharmaceutically acceptable salts thereof, for evening dosing every 24 hours containing from about 180 mg to about 420 mg of the form of Diltiazem with excipients to provide controlled (sustained) release of the form of Diltiazem from the preparation for providing a Cmax of Diltiazem in the blood at between about 10 hours and about 17 hours (Tmax) after administration of the preparation, the preparation being in a sustained-release dosage form in which the Diltiazem is adapted to be control released after administration of the preparation over a period of time wherein the preparation comprises a plurality of microgranules, each microgranule comprising a central core containing the form of diltiazem coated with a microporous membrane and the central core comprises Diltiazem or pharmaceutically acceptable salt thereof associated with a wetting agent in which the core and membrane comprise:
Dependencies are inferred from the claim text.